The Epicenter of Biomanufacturing Strategy
Future-Proof Your Manufacturing Strategy
Manufacturing is no longer a late-stage operational concern - it's an early strategic decision that determines partnership success, investment readiness, and long-term commercial viability.
Future-Proofing Innovation from Day One
At BIO-Europe 2026, we're introducing a dedicated Biomanufacturing Strategy Track that asks the critical question: What manufacturing decisions should you make today to avoid bottlenecks in 5-10 years?
Discover how early strategic choices unlock partnership potential, accelerate investment readiness and drive long-term commercial viability. This is where forward-thinking leaders turn manufacturing into competitive advantage.
Strategic frameworks for embedding manufacturing considerations into early development
Lessons learned from biotech leaders who successfully scaled from concept to commercialization
Insights into how manufacturing strategy influences investment decisions and partnership attractiveness
Fireside conversations exploring CDMO-partner collaborations that evolved beyond transactional relationships
The Biomanufacturing Strategy Track Is For
Senior leadership executives and decision-makers responsible for bioprocessing strategy, manufacturing partnerships, and commercialization planning in small to mid-size biotech, large pharma, CDMO, and related biopharmaceutical companies.
C-level Leadership:
- Founder
- Chief Executive Officer (CEO)
- Chief Operating Officer (COO)
- Chief Manufacturing Officer (CMO)
- Chief Technical Officer (CTO)
- Chief Quality Officer (CQO)
- Chief Strategy Officer (CSo)
Senior Vice Presidents and Vice Presidents of:
- Manufacturing & Operations
- Technical Operations
- Process Development
- Quality & Compliance
- Supply Chain Logistics
- Strategic Partnerships
Global Directors / Heads of:
- Bioprocessing & Biomanufacturing
- Manufacturing Strategy
- Technology Transfer
- Facility Planning & Design
- CDMO Partnerships
- Manufacturing Innovation
Learn More About Participating
FAQs
Why is BIO-Europe introducing a Biomanufacturing Strategy track?
As the biotech industry shifts toward advanced therapies and complex modalities, integrating manufacturing strategy from day one has become essential. BIO-Europe is responding to this transformation by creating a forum where strategic manufacturing conversations happen during early development and partnering discussions.
How does Biomanufacturing Strategy align with BIO-Europe's partnering focus?
Whether you're seeking licensing agreements, co-development opportunities, or investor backing, your manufacturing strategy influences how partners evaluate risk, scalability, and long-term value. This track positions manufacturing as a strategic enabler of partnerships - not an afterthought - helping attendees make informed decisions that strengthen deal attractiveness and partnership outcomes.
Isn't manufacturing too far along in the product lifecycle for a partnering event?
That's exactly the misconception this track addresses. Waiting until late-stage development to consider manufacturing creates costly bottlenecks, limits partnership options, and can derail commercialization. This track focuses on future-proofing the biotech industry.
Who should attend the Biomanufacturing Strategy track?
This track is designed for decision-makers who recognize that manufacturing strategy impacts business outcomes:
- Early to mid-stage biotech CEOs and COOs planning for scale
- C-suite executives (CSOs, CMOs, CQOs) making strategic manufacturing decisions
- Investors and VCs evaluating manufacturing readiness during due diligence
- Business Development professionals seeking to understand how manufacturing influences partnership value
- Cell & Gene Therapy companies navigating complex early-stage manufacturing challenges
If you're involved in partnerships, investment, or strategic planning, this content is relevant to your role.
What makes this different from other biomanufacturing conferences?
This track focuses on strategic decision-making at the intersection of manufacturing, partnerships, and investment. It's not about how to run a bioreactor - it's about how manufacturing strategy influences deal flow, funding decisions, and competitive positioning. This is manufacturing through a business lens, designed specifically for the BIO-Europe audience.
What topics will the Biomanufacturing Strategy track cover?
Expect forward-thinking content on:
- Future-proofing manufacturing for advanced therapies and novel modalities
- Integrating manufacturing strategy into early development and partnership planning
- Manufacturing readiness as an investment criterion
- Transforming CDMO relationships from transactional to strategic
- Lessons learned from biotechs that scaled successfully—and those that didn't
- Emerging innovations reshaping biomanufacturing over the next decade